PACB NASDAQ
Pacific Biosciences of California, Inc.
1W: +25.0%
1M: +43.3%
3M: +75.0%
YTD: +33.1%
1Y: +21.3%
3Y: -66.8%
5Y: -90.3%
$2.45
+0.20 (+8.89%)
Weekly Expected Move ±21.8%
$1
$2
$2
$3
$3
Credit Risk of going bust: higher than 91% of companies Debt: 48.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.29 (down 88%), Pacific Biosciences of California, Inc. would be worth roughly what it owes.
Total debt $706.1M against a stock market value of $761.5M.
Distance to default 1.52 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $322.2M (short-term plus half of long-term), stock volatility 92.2%; Altman Z -4.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.29 (down 88%), Pacific Biosciences of California, Inc. would be worth roughly what it owes.
Total debt $706.1M against a stock market value of $761.5M.
Distance to default 1.52 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $322.2M (short-term plus half of long-term), stock volatility 92.2%; Altman Z -4.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships18
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-07-20
Earliest Filing
2026-02-02
Latest Filing
partner: 7
acquirer: 5
investor: 4
target: 2
Counterparties (Filed by PACB)
18 relationshipsCompanies named in PACB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Illumina Cambridge Limited | ILMN | acquirer | Acquired short-read DNA sequencing technology and related assets from Pacific Biosciences of California, Inc. | 2026-02-02 | View |
| Illumina, Inc. | ILMN | partner | Signatory to the Asset Purchase Agreement alongside Pacific Biosciences of California, Inc. and Illumina Cambridge Limit | 2026-02-02 | View |
| SB Northstar LP | — | investor | Holder of 2028 Notes exchanged for New Notes, Exchange Shares, and cash payment. | 2024-11-22 | View |
| SB Northstar LP | — | investor | Holder of 2028 Notes exchanging them for New Notes, Exchange Shares, and cash payment. | 2024-11-07 | View |
| Chimera Investment LLC | CIMO | investor | Holder of 2028 Notes exchanged for New Notes in a private placement | 2023-06-30 | View |
| Chimera Investment LLC | CIMO | investor | Counterparty in a private exchange transaction for convertible notes | 2023-06-26 | View |
| Goldman Sachs & Co. LLC | GSCE | partner | Underwriter for the common stock offering | 2023-01-27 | View |
| Morgan Stanley & Co. LLC | MS-PL | partner | Underwriter for the common stock offering | 2023-01-27 | View |
| Cowen and Company, LLC | — | partner | Underwriter for the common stock offering | 2023-01-27 | View |
| Invitae Corporation | NVTA | partner | Amended and restated development and commercialization agreement for sequencing systems | 2022-06-30 | View |
| Omniome, Inc. | — | target | Target company acquired by Pacific Biosciences of California, Inc. in a merger completed on September 20, 2021. | 2021-09-20 | View |
| Apollo Acquisition Corp. | — | acquirer | Wholly owned subsidiary of Pacific Biosciences of California, Inc. that entered into the Merger Agreement. | 2021-09-20 | View |
| Apollo Acquisition Sub, LLC | — | acquirer | Wholly owned subsidiary of Pacific Biosciences of California, Inc. that entered into the Merger Agreement. | 2021-09-20 | View |
| Shareholder Representative Services, LLC | — | partner | Securityholder representative party to the Merger Agreement. | 2021-09-20 | View |
| Omniome, Inc. | — | target | Target company in the acquisition of Omniome, Inc. by Pacific Biosciences of California, Inc. | 2021-07-20 | View |
| Apollo Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Pacific Biosciences of California, Inc. used as the acquiring entity in the merger. | 2021-07-20 | View |
| Apollo Acquisition Sub, LLC | — | acquirer | Wholly owned subsidiary of Pacific Biosciences of California, Inc. involved in the merger agreement. | 2021-07-20 | View |
| Shareholder Representative Services, LLC | — | partner | Securityholder representative appointed to represent Omniome's stockholders in the merger agreement. | 2021-07-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exit/Disposal Costs; Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-07-09 | Officer/Director Change | View | |
| 2026-06-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-06 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure | View | |
| 2026-03-05 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-02 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Regula | Agreement Acquisition | View |
| 2026-01-12 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-06 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-09 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; Fi | View | |
| 2025-03-27 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-03-13 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2025-02-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-07 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-01-30 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR